In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.
On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked
Many people are troubled by stomach problems for many years, so what is the reason? Bad habits and mental stress were once considered to be major factors, but there is another reason that must be mentioned, that is, Helicobacter pylori. I. Discovery of Helicobacter pylori In 1982, Australian… Continue Reading Do you know about Helicobacter pylori?
Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer
Biopharma Dive, a biopharmaceutical website, recently selected the annual pharmaceutical company (Mersha East), the annual biotechnology company (Spark Therapeutics), the annual CEO (Emma Walmsley, GSK), the annual transaction (Takeda $62 billion acquisition of Shire), the annual innovation (RNA Targeted therapy), an annual new drug (Ajin/Nuohua migraine drug Aimovig). … Continue Reading BioPharma: Six “most” in 2018
On November 30, Pfizer announced a settlement with AbbVie on a worldwide patent litigation against adalimumab biosimilars. Under the agreement, in the European market, Pfizer’s adalimumab biosimilars will be available for sale upon approval by the EMA. However, in the US market, Pfizer needs to market adalimumab biosimilars on… Continue Reading Pfizer and AbbVie reach a settlement, delaying the launch of Humira-like drugs in the US